aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12 août 2022 16h05 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Aug. 12, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on its proprietary...
aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis
11 août 2022 08h03 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Aug. 11, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or “the Company”), a clinical stage biotherapeutics company engaged in the discovery and development of...
aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2022 Financial Results
04 août 2022 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
Life & Banc Split Corp. Completes Treasury Offering
27 juil. 2022 08h43 HE
|
Life & Banc Split Corp.
Not for distribution to U.S. newswire services or for dissemination in the United States. TORONTO, July 27, 2022 (GLOBE NEWSWIRE) -- (TSX: LBS, LBS.PR.A) Life & Banc Split Corp. (the...
Life & Banc Split Corp. Announces Successful Overnight Offering
20 juil. 2022 14h11 HE
|
Life & Banc Split Corp.
Not for distribution to U.S. newswire services or for dissemination in the United States. TORONTO, July 20, 2022 (GLOBE NEWSWIRE) -- (TSX: LBS, LBS.PR.A) Life & Banc Split Corp. (the...
aTyr Pharma Announces FGFR4 as Receptor Target for AARS tRNA Synthetase Fragment
14 juin 2022 08h00 HE
|
aTyr Pharma, Inc.
Poster to be presented at the Keystone Symposia on Tissue Fibrosis and Repair. Second tRNA synthetase receptor identified from company’s platform. Findings suggest AARS fragment may have...
aTyr Pharma to Present Findings from its tRNA Synthetase Platform at the International 28th tRNA Conference
13 juin 2022 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, June 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
aTyr Pharma to Present at the 2022 Jefferies Healthcare Conference
01 juin 2022 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines from its proprietary tRNA...
aTyr Pharma Presents Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference
17 mai 2022 08h00 HE
|
aTyr Pharma, Inc.
Results from Phase 1b/2a study of efzofitimod in pulmonary sarcoidosis patients demonstrate dose-dependent improvements in key physiologic and quality of life measures in context of a steroid taper. ...
aTyr Pharma Announces Phase 3 Study of Efzofitimod (ATYR1923) in Pulmonary Sarcoidosis
16 mai 2022 08h00 HE
|
aTyr Pharma, Inc.
Global pivotal EFZO-FIT™ study expected to begin in the third quarter of 2022 Primary endpoint will evaluate steroid sparing effect of efzofitimod compared to placebo SAN DIEGO, May 16, 2022 ...